← Back to Clinical Trials
Recruiting NCT06072066

NCT06072066 Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06072066
Status Recruiting
Phase
Sponsor Integrative Skin Science and Research
Condition Rosacea
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2023-11-22
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Skin Barrier Oral Supplement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2023-11-22 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.

Eligibility Criteria

Inclusion Criteria: * Males and females 30 to 70 years of age * The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular) * High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg/L Exclusion Criteria: * The presence of severe rosacea as noted by the investigator global assessment. * Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment. * Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment * Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment. * Those who are unwilling to keep their facial regimen the same throughout the study. * Individuals who have been on an oral antibiotic within the previous one month. * Individuals who are pregnant or breastfeeding. * Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study. * Individuals on oral contraceptive pills or progesterone or estrogen containing therapies. * Use of isotretinoin within the three months prior to enrollment. * Individuals on finasteride or dutasteride * Current tobacco smoker, smoker within the past year, or greater than 5 pack-year tobacco smoking history.

Contact & Investigator

Central Contact

Caitlin Egli

✉ research@integrativeskinresearch.com

📞 916-750-2463

Frequently Asked Questions

Who can join the NCT06072066 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 70 Years, studying Rosacea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06072066 currently recruiting?

Yes, NCT06072066 is actively recruiting participants. Contact the research team at research@integrativeskinresearch.com for enrollment information.

Where is the NCT06072066 trial being conducted?

This trial is being conducted at Sacramento, United States.

Who is sponsoring the NCT06072066 clinical trial?

NCT06072066 is sponsored by Integrative Skin Science and Research. The trial plans to enroll 24 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology